Expression of VCAN and its receptors in canine mammary carcinomas with or without myoepithelial proliferation

Figueredo, Susy; Neto, Rosário; Ferreira, Ênio; Cassali, Geovanni Dantas; Estrela‐Lima, Alessandra; Damasceno, Karine Araújo

doi:10.1016/j.rvsc.2021.08.010

Cited by 2 publications

(3 citation statements)

References 38 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significantly, alterations in the structure or expression of EGFR can trigger tumorigenesis, and the EGFR-STAT3-PD-L1 pathway plays crucial roles in cancer growth and metastasis. Inhibiting this pathway can effectively reduce cancer migration and invasion, suggesting potential therapeutic targets in the treatment of cSCC [64][65][66]. Therapy for cSCC with EGFR inhibitors, including monoclonal antibodies (e.g., cetuximab and panitumumab) and tyrosine kinase inhibitors (gefitinib and erlotinib), has emerged as a promising approach.…”

Section: Discussionmentioning

confidence: 99%

“…Therapy for cSCC with EGFR inhibitors, including monoclonal antibodies (e.g., cetuximab and panitumumab) and tyrosine kinase inhibitors (gefitinib and erlotinib), has emerged as a promising approach. However, the efficacy of these treatments in human cSCCs is variable [64][65][66]. EGFR inhibitors are better tolerated than chemotherapy, making them a preferred option for human patients who are elderly or have multiple health issues.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Luís,

Files,

Cardoso

et al. 2024

CIMB

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) stands as the second most prevalent skin cancer in dogs, primarily attributed to UV radiation exposure. Affected areas typically include regions with sparse hair and pale or depigmented skin. The significance of spontaneous canine cutaneous SCC as a model for its human counterpart is underscored by its resemblance. This study assesses the expression of key markers—Epidermal Growth Factor Receptor (EGFR), Cyclooxygenase-2 (Cox-2), and Ki-67—in canine cutaneous SCC. Our objective is to investigate the association between their expression levels and classical clinicopathological parameters, unraveling the intricate relationships among these molecular markers. In our retrospective analysis of 37 cases, EGFR overexpression manifested in 43.2% of cases, while Cox-2 exhibited overexpression in 97.3%. The EGFR, Cox-2 overexpression, and Ki-67 proliferation indices, estimated through immunohistochemistry, displayed a significant association with the histological grade, but only EGFR labeling is associated with the presence of lymphovascular emboli. The Ki-67 labeling index expression exhibited an association with EGFR and Cox-2. These findings propose that EGFR, Cox-2, and Ki-67 hold promise as valuable markers in canine SCC. EGFR, Cox-2, and Ki-67 may serve as indicators of disease progression, offering insights into the malignancy of a lesion. The implications extend to the potential therapeutic targeting of EGFR and Cox-2 in managing canine SCC. Further exploration of these insights is warranted due to their translational relevance and the development of targeted interventions in the context of canine SCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Luís,

Files,

Cardoso

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

“…The expression of versican has been related to invasion and progression in malignant mixed tumors, such as carcinoma in mixed tumors (CMT) of the canine mammary gland. In addition, its interaction with surface cell receptors EGFR, human epidermal growth factor receptor 2(HER-2) and CD44 in malignant epithelial cells may be responsible for proliferation and cellular motility in early stages of cancer [27]. Versican V1 was also found to promote the Warburg effect and cell proliferation in other cancers, including breast cancer [28].…”

Section: Discussionmentioning

confidence: 99%

Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

Background and aims This study aimed to investigate the expression of plasma versican and plasma exosomal versican in non-small cell lung cancer (NSCLC) and its correlation with clinicopathological features, and to evaluate its diagnostic performance in NSCLC and its predictive function for NSCLC incidence and metastasis risk. Materials and methods There were 110 instances of NSCLC, 42 cases of benign lung disease, and 55 healthy controls from September 2018 to October 2020 at Tongji Hospital Affiliated to Tongji University. Blood was collected and plasma was separated before surgery, and plasma exosomes were extracted by ExoQuick kit. Morphological and molecular phenotype identification of exosomes was performed by transmission electron microscopy, Nanosight particle tracking analysis, and western blotting. Plasma versican and plasma exosomal versican were detected in all subjects to assess their expression levels and diagnostic value in NSCLC. Clinicopathological data were collected to explore correlations between abnormal plasma versican and plasma exosomal versican expression and clinicopathological parameters. Receiver operating characteristic (ROC) curve was used to judge its diagnostic performance in NSCLC, and binary logistic regression analysis was used to predict the risk of NSCLC incidence and metastasis. Results Plasma versican and plasma exosomal versican expression in NSCLC patients was significantly upregulated and was significantly higher in T3 + T4 patients compared with T1 + T2 patients (P < 0.05); the levels of plasma versican and plasma exosomal versican were positively correlated with lymph node metastasis, distant metastases (e.g., brain, bone), and mutation(e.g., EGFR,ALK)in NSCLC patients (all P < 0.05). Furthermore, ROC curve analysis showed that plasma versican and plasma exosomal versican had higher AUC values than NSE, CYFRA21-1, and SCC, and better diagnostic performance in NSCLC patients. However, the AUC and diagnostic performances of plasma versican and plasma exosomal versican in advanced-stage NSCLC patients were not shown to be significantly better than CEA. The results of binary logistic regression analysis showed that high levels of plasma exosomal versican had higher predictive value for lung cancer incidence, while high levels of plasma versican had higher predictive value for lung cancer metastasis. Conclusion Our findings showed that plasma versican and plasma exosomal versican might be potential diagnostic markers for NSCLC. High plasma exosomal versican expression can be used as a predictor of NSCLC risk and high plasma versican expression can be used as a predictor of NSCLC metastasis risk.

show abstract

Expression of VCAN and its receptors in canine mammary carcinomas with or without myoepithelial proliferation

Cited by 2 publications

References 38 publications

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer

Contact Info

Product

Resources

About